Experimental combo aims to revive immune attack on tough lymphoma
NCT ID NCT05162976
First seen Jun 07, 2026 · Last updated Jun 15, 2026 · Updated 2 times
Summary
This early-phase study tests whether adding an oral drug (CC-486) to the immunotherapy nivolumab can help people with Hodgkin lymphoma whose cancer did not respond to PD-1 therapy. CC-486 may make cancer cells more visible to the immune system, potentially restoring nivolumab's effectiveness. The trial involves 33 adults and focuses on safety and tumor shrinkage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT CLASSIC HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
Conditions
Explore the condition pages connected to this study.
Conditions inferred from the trial description
These were inferred from the trial's summary, not listed by the trial registrant.